Bluejay Diagnostics, Inc.·4

May 18, 5:20 PM ET

Dey Indranil 4

Research Summary

AI-generated summary

Updated

Bluejay Diagnostics (BJDX) CEO Indranil Dey Buys Stock

What Happened
Indranil Dey, President, CEO and a director of Bluejay Diagnostics (BJDX), purchased 12,500 shares of the company's common stock in a private placement on March 14, 2026. The shares were bought from the issuer at $2.00 per share, for a total cash outlay of $25,000. This was a purchase (transaction code P), which is often viewed as a bullish signal, though the filing does not state his motivation.

Key Details

  • Transaction date: March 14, 2026 — Private placement purchase at $2.00 per share.
  • Shares acquired: 12,500; Total value: $25,000.
  • Filing date (Form 4): May 18, 2026 — the report was filed well after the transaction date (reporting delay).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Footnotes:
    • F1: Confirms the purchase was from the issuer in a private placement.
    • F2: Lana Management & Business Research International, LLC is owned by Mr. Indranil Dey and Ms. Svetlana Dey; Mr. Dey has voting and dispositive power over shares held by that entity.

Context
This was a direct purchase from the company (private placement), not an open-market buy — private placements can be part of financing or other issuer-directed transactions. The dollar amount is modest ($25k) relative to many insider transactions. The late filing means the disclosure came well after the two-business-day window normally required for Form 4s; investors should note the timing when evaluating the trade.